Abstract：Objective To explore the risk factors leading to increased blood pressure of Apatinib in the treatment of malignant tumors.Methods A total of 240 cases of malignant tumor patients in the First Affiliated Hospital of Gannan Medical College from January 2018 to December 2019 were selected as the research objects,and they were divided into the observation group and the control group according to different treatment methods,120 cases in each group.The observation group was treated with Apatinib,while the control group was treated with routine therapy,without Apatinib.The incidence of increased blood pressure were compared between the two groups.At the same time,the general data of patients in the observation group were retrospectively analyzed,and the common risk factors of hypertension were evaluated by univariate analysis and Logistic regression analysis.Results The incidence of hypertension in the observation group was 35.0%,which was higher than that in the control group (10.0%) (P＜0.05).There was no hypertension crisis in the two groups,and the blood pressure was controlled after drug treatment.Univariate analysis showed that age,smoking history,body mass index (BMI),Estern Cooperative Oncology Group (ECOG) score,medication dose were related to the occurrence of secondary hypertension caused by apatinib (P＜0.05).Logistic regression analysis showed that age was an independent risk factor for secondary hypertension caused by Apatinib (P＜0.05).Conclusion Age is closely related to the secondary hypertension caused by Apatinib.It is necessary to pay more attention to the observation of elderly patients′ condition.
何苗；曹佐锋；黄莉. 阿帕替尼治疗恶性肿瘤致血压升高的危险因素分析[J]. 中国当代医药, 2020, 27(35): 136-139.
HE Miao； CAO Zuo-feng； HUANG Li. Analysis of risk factors leading to increased blood pressure caused by Apatinib in the treatment of malignant tumors. 中国当代医药, 2020, 27(35): 136-139.
京公网安备 11010502046607号